Gout Pipeline Assessed: Over 40 Companies Developing Therapies
An assessment of the gout therapeutics pipeline reveals over 40 companies are developing new treatments. Selecta Biosciences' candidate, SEL-212, is in the most advanced, Phase III, stage of clinical development.
More than 40 pharmaceutical companies are actively investigating new treatment modalities for gout, a chronic condition stemming from the excessive accumulation of uric acid in the body. Selecta Biosciences' candidate, SEL-212, is currently in Phase III clinical trials, representing the most advanced therapy in development.
The 'Gout Pipeline Insights' report by DelveInsight details over 40 distinct therapeutic candidates across various development stages, from preclinical to Phase III. The analysis covers marketed and emerging therapies, including ongoing clinical trials, regulatory approvals, and the strategic approaches of key players in the field.
Companies such as Protalix BioTherapeutics, Shanton Pharma, Horizon Therapeutics, and LG Chem are among those at the forefront of development. Many of these emerging treatments aim to improve uric acid management and reduce the inflammation associated with gout.
The report also highlights significant collaborations, including the licensing agreement between Swedish Orphan Biovitrum AB and Selecta Biosciences for SEL-212. Additionally, Fortress Biotech has secured rights to develop and market Dotinurad in North America and Europe. Arthrosi Therapeutics has formed a joint venture in China for the development of AR882 in the region.
Gout is a painful disease characterized by the deposition of uric acid crystals in the joints. While manageable through diet and lifestyle changes, new pharmacological interventions offer the potential for improved disease control and enhanced patient quality of life.